Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth …